DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time

Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

(2011) Supriya Perambakam et al.   Clinical & Developmental Immunology

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen

(2011) Gisella E. Vittes et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in prostate cancer: Emerging strategies against a formidable foe

(2011) Marijo Bilusic et al.   VACCINE

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond

(2010) C. M. Britten et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies

(2010) K. Rezvani et al.   HAEMATOLOGICA

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Regulation of Cancer

(2010) Mary L. Disis   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

(2009) James L. Gulley et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer

(2009) Hirotsugu Uemura et al.   CANCER SCIENCE

DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer

(2009) Lindsey Low et al.   HUMAN GENE THERAPY

“MIATA”—Minimal Information about T Cell Assays

(2009) Sylvia Janetzki et al.   IMMUNITY

The relationship between human effector and memory T cells measured byex vivoand cultured ELISPOT following recent and distal priming

(2009) Stephen M. Todryk et al.   IMMUNOLOGY

Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer

(2009) Douglas G. McNeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax)

(2009) Robert J. Amato et al.   JOURNAL OF IMMUNOTHERAPY

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer

(2009) Susan Feyerabend et al.   PROSTATE

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance

(2008) C. Chaise et al.   BLOOD

Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines

(2008) Ann Mander et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

(2008) R. Dreicer et al.   INVESTIGATIONAL NEW DRUGS

Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time

(2008) Philip M. Arlen et al.   JOURNAL OF UROLOGY